Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 8/26/14  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Matthew Pollman

Wrong Dr. Matthew Pollman?

Chief Executive Officer

Guided Interventions , LLC
 
Background

Employment History

Board Memberships and Affiliations

Education

  • M.D
  • M.D.
17 Total References
Web References
Juventas Therapeutics: Board of Directors
www.juventasinc.com, 26 Aug 2014 [cached]
Matthew Pollman, M.D. - Matthew Pollman, M.D. is a cardiologist and cardiovascular molecular biologist with over ten years of experience leading R&D initiatives in the biotechnology, diagnostics, and medical devices healthcare arenas. He is currently the CEO of Guided Interventions, LLC, a startup company developing a product to help cardiologists better assess the physiological impact of coronary artery blockages. Prior to this latest venture, Dr. Pollman served as Founder, President and Chief Scientific Officer of CV Ingenuity, an early stage company developing a combination drug/device therapy for the treatment of cardiovascular disease, recently acquired by Covidien. Additionally, he has served as Medical Director, Research and Development, Abbott Vascular serving as principal medical and scientific strategist and advisor for the R&D pipeline and Business Development portfolios guiding both internal and external technology investments. Prior to Abbott's acquisition of Guidant Corporation, Dr. Pollman directed their New Ventures group, a 30+ member in-house start-up incubator responsible for identifying, exploring and incubating significant new business opportunities. Dr. Pollman received his medical training at the University of California San Francisco, Stanford University and Brigham and Women's Hospital. He has served as a full-time faculty member at Harvard Medical School and Morehouse School of Medicine.
Attraction Program Advisory Board | GCIC | Global Cardiovascular Innovation Center in Cleveland, Ohio
gcic.org, 30 Aug 2014 [cached]
Matt Pollman, MD
...
Matt Pollman, MD
Consultant, Cardiovascular Therapeutic and Diagnostics
...
Matthew Pollman, consultant, has held a number of leadership positions in the development of cardiovascular therapeutics and diagnostics. He has most recently served as Medical Director, R&D, for Abbott Vascular. In this role, Dr. Pollman was the principal medical and scientific advisor for the R&D and Business Development organizations. Prior to this role, Dr. Pollman was the Director of New Ventures, Guidant Corporation where he led a multi-disciplinary in-house start-up incubator tasked with identifying, exploring and incubating through PhI/PhII clinical trials, novel therapeutic opportunities utilizing emerging device or combination product technologies. Dr. Pollman has also directed therapeutic/diagnostic target discovery and development efforts as Director of Cardiovascular Biology and Molecular Medicine for Millennium Pharmaceuticals. Dr. Pollman is a cardiologist and cardiovascular molecular biologist and has authored numerous peer-reviewed journal articles. He has served on the faculties of Harvard Medical School and Morehouse School of Medicine.
CV Ingenuity | Team
www.cvingenuity.com, 20 Mar 2013 [cached]
Matthew Pollman, M.D
Scientific Advisor
Matthew Pollman, M.D., is the co-founder and Scientific Advisor for the company. Dr. Pollman is a cardiologist and cardiovascular molecular biologist with over 15 years of experience leading R&D initiatives in the biotechnology, diagnostics, and medical devices healthcare arenas. He has served as Medical Director for Abbott Vascular, directed the New Ventures organization for Guidant Corporation and led cardiovascular biology and personalized medicine initiatives at Millennium Pharmaceuticals. Dr. Pollman is a board member of the Global Cardiovascular Innovation Center's commercial advisory board at the Cleveland Clinic and serves on the Board of Directors for Merlot OrthopediX, Juventas Therapeutics and NaviGate Cardiac Structures. Dr. Pollman received his medical and research training at the University of California San Francisco, Stanford University and Brigham and Women's Hospital.
Innovation + Job News
www.hiVelocityMedia.com, 16 May 2013 [cached]
The company was formed two years ago and has been mainly focused on developing its intellectual property and proof of concepts, says Guided Interventions CEO Matthew Pollman.
"The concept is revolutionary," Pollman says. "It uses a pressurized guideline to measure fractional flow reserve (FFR). It facilitates assessing blockages in the coronary artery and determines whether to perform an intervention."
Pollman cites a clinical study, published in the New England Journal of Medicine, that showed using technologies like Guided Interventions' FFR product instead of traditional angiogram indicate that 37 percent of the time the blockage should be left alone. "Sometimes leaving it alone is actually the best thing for patients," he says.
Pollman plans to use the JumpStart investment to build out operations at GLIDE and the SMART Commercialization Center for Microsystems at Lorain County Community College.
The money will also allow the company to hire as many as six employees in the next two years, in particular engineers, and then triple or even quadruple the number of employees in the next three to five years. Currently, Pollman and his partner, Reinhard Warnking, are the only two employees.
...
Pollman, who is in the process of moving to Northeast Ohio from California, says he is looking forward to moving to a region that is so supportive of startup biotechnology companies and research.
Source: Matthew Pollman
The company was formed two years ...
www.jumpstartinc.org, 17 Jan 2013 [cached]
The company was formed two years ago and has been mainly focused on developing its intellectual property and proof of concepts, says Guided Interventions CEO Matthew Pollman.
"The concept is revolutionary," Pollman says. "It uses a pressurized guideline to measure fractional flow reserve (FFR). It facilitates assessing blockages in the coronary artery and determines whether to perform an intervention."
Pollman cites a clinical study, published in the New England Journal of Medicine, that showed using technologies like Guided Interventions' FFR product instead of traditional angiogram indicate that 37 percent of the time the blockage should be left alone. "Sometimes leaving it alone is actually the best thing for patients," he says.
Other People with the name "Pollman":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304